Introduction
============

Human embryonic stem cells (hESCs) are isolated from the inner cell mass of the developing blastocyst, indefinitely maintaining their capability for self-renewal and pluripotent nature ([@B32]). By taking advantage of hESC characteristics, studies on early human development, drug development, and cell-based therapies for incurable diseases have become possible ([@B9]). However, ethical issues have arisen, since hESCs are derived from pre-implantation human embryos ([@B29]). Moreover, challenging obstacles associated with immune rejection after transplantation for cell-replacement therapy remained unresolved.

As a breakthrough discovery in regenerative medicine, adult human fibroblasts have been successfully reprogrammed via overexpression of pluripotency-related transcription factors, which include *OCT4* (*POU5F1*), *SOX2*, *KLF4*, and *c-MYC*, to establish human induced pluripotent stem cells (hiPSCs) ([@B31]). Many studies have demonstrated close similarities between hiPSCs and hESCs at the molecular and genetic level, and in terms of their morphologies and functions ([@B18]; [@B4]; [@B10]). Disease-specific iPSC lines also are accessible since they can be generated from patients with sporadic or genetically inherited diseases ([@B6]; [@B25]; [@B19]; [@B30]; [@B2]; [@B33]). The hESC-like characteristics allow them to be differentiated into various cell types in response to developmental cues. Recent reports have described that cell types related to the respective disorder are differentiated from disease-specific iPSCs and have been able to faithfully recapitulate disease phenotypes ([@B7]; [@B15]; [@B11]; [@B17]; [@B35]). This landmark discovery of hiPSCs has opened a new window for developing human disease models *in vitro* in order to investigate pathophysiology and drug development ([@B20]; [@B27]; [@B12]; [@B23]; [@B34]). Although the recent studies have shown substantial differences between hiPSCs and hESCs at the transcriptional, epigenetic, genetic and functional levels ([@B8]; [@B24]), the value of hiPSCs has been proven as a useful tool for *in vitro* disease modeling.

Herein, we report the generation and characterization of hiPSCs from fibroblasts of patients who have been previously diagnosed with sporadic or familial diseases including Parkinson\'s disease (PD), Alzheimer\'s disease (AD), juvenile-onset, type I diabetes mellitus (JDM), and Duchenne type muscular dystrophy (DMD), as well as from normal human fibroblasts (WT). The disease-specific hiPSCs can be differentiated into cell-types of their relevant diseases. Therefore, these disease-specific hiPSCs hold great potential for research and clinical purposes by providing a useful platform for disease modeling and drug screening. As recently reported, we have established childhood cerebral adrenoleukodystrophy (CCALD)- and adrenomyeloneuropathy (AMN)-iPSCs, and, as a proof-of-principle, modeled its diseases ([@B12]). In this study, we generated PD-specific DA neurons from the hiPSCs derived from fibroblasts of PD patients. The possibility of applying the PD-specific cell models to research and clinical purposes is currently under investigation.

Results and Discussion
======================

Establishment and characterization of disease-specific hiPSC lines
------------------------------------------------------------------

Patient-derived disease-specific fibroblasts and normal neonatal human dermal fibroblasts were reprogrammed by retroviral-mediated delivery of four defined factors (*OCT4*, *SOX2*, *KLF4*, and *c-MYC*) ([Table 1](#T1){ref-type="table"}). After transduction, the fibroblasts were cultured for about 4-5 weeks on a feeder layer until hESC-like colonies appeared. The colonies were picked mechanically and cultured on feeder cells for expansion. Since the early-passage hiPSCs showed a tendency of losing their stemness or spontaneous differentiation, we selected colonies that were passage 10 or more to establish stable hiPSC lines. These bona fide iPSC lines might be derived from either the fully reprogrammed cells or epigenetic adjustment of the early-passage reprogrammed cells during continued serial passages ([@B21]; [@B26]). Consistently, the previous report showed that extended passaging enabled the global gene expression pattern of hiPSCs similar to that of hESCs ([@B3]; [@B24]).

To confirm the presence of hESC-like characteristics, the expanded iPSC colonies were characterized at the molecular and genetic level; the colonies showed significant expression of multiple undifferentiation markers such as alkaline phosphatase (AP), OCT4, SOX2, NANOG, SSEA4, TRA-1-81, and TRA-1-60 ([Figure 1](#F1){ref-type="fig"}). In addition, quantitative real-time PCR (qRT-PCR) analysis also demonstrated comparable level of expression of the well-known undifferentiation marker genes including *OCT4*, *SOX2*, *KLF4*, *c-MYC*, *NANOG*, and *hTERT*, as in H9-hESCs ([Figure 2](#F2){ref-type="fig"}). In harmony with the previous observations, the exogenously introduced transgenes were silenced in iPSC lines while high expressions of pluripotency genes (*OCT4*, *SOX2*, *KLF4*, and *c-MYC*) were found from endogenous loci ([Figure 3](#F3){ref-type="fig"}). Bisulfite genomic sequencing analyses showed that *OCT4* promoter regions were hypomethylated in disease-specific hiPSCs relative to the parental fibroblasts (data not shown). DNA fingerprint analysis of short tandem repeats (STRs) revealed that each established hiPSC line was identical to its parental somatic cell line ([Table 2](#T2){ref-type="table"}). No aneuploidy was observed in all of the hiPSC lines ([Figure 4](#F4){ref-type="fig"}). Although each hiPSC line is morphologically indistinguishable and meets the gold standard requirements for hiPSCs, the colonies vary in the extent of pluripotent marker expression and transgene silencing of hiPSCs, which was potentially caused by differential viral integration, culture conditions, passage number, and batch effects ([@B24]). In addition, differences in origin, the epigenetic signatures and the genetic background of the patients\' somatic cells used for reprogramming might also influence the variability in reprogramming status of the hiPSCs obtained ([@B21]; [@B14]). For example, Raya et al. showed that somatic cells from patients with Franconi\'s anemia (FA) were refractory to reprogramming, making it difficult to model such condition *in vitro*, due to the genetic instability and apoptotic predisposition of FA cells. They successfully generated hiPSCs from patients with FA only after correction of FA-related gene ([@B28]).

Human pluripotent stem cells including hiPSCs have the ability to differentiate into all three embryonic germ layers: ectoderm, endoderm, and mesoderm. It was reported that early-passage iPSC lines have the tendency of differentiate preferentially into the cell lineage of origin and continuous passaging abrogates these preferences in the differentiation potentials to established iPSCs ([@B3]; [@B26]). Using the previously described method ([@B13]), embryoid bodies (EBs) were formed from the iPSC lines at over 10 passages in order to avoid preferential differentiation potentials, and then allowed to spontaneously differentiate into three germ layers. Ectodermal lineages were confirmed by expressions of Nestin and Pax6, while endodermal lineages were determined through expressions of HNF3β and AFP. Expressions of brachyury, on the other hand, confirmed mesodermal lineages of spontaneously differentiated iPSC lines ([Figure 5](#F5){ref-type="fig"}).

Taken together, these data indicate that primary fibroblasts from patients with sporadic or familial diseases were successfully reprogrammed into hiPSCs.

Differentiation of disease-specific hiPSCs into disease-relevant cells: disease modeling and platforms for new drug discovery
-----------------------------------------------------------------------------------------------------------------------------

One of the most important aspects of hiPSC technology is modeling human diseases using patient-derived hiPSCs. Recapitulation of phenotypes of relevant diseases using disease-specific hiPSCs would provide a unique opportunity to study etiopathophysiology of the diseases and to develop new therapeutic regimens or drugs. To generate cell models of diseases, differentiation of disease-specific iPSCs into cell types relevant to the diseases is absolutely required.

In an effort to establish cell models of PD, we sought to differentiate PD-iPSCs into DA neurons which are mostly affected in PD by introducing morphogens and neurotrophins ([@B5]). As previously reported ([@B13]), BMP and Activin/Nodal signals were simultaneously inhibited by introduction of small molecules such as dorsomorphin (DM) and SB431542 (SB) during EB formation to obtain neural rosette structures. Using sonic hedgehog homolog (SHH) and fibroblast growth factor 8 (FGF 8), we regionalized PD-iPSC-derived neural rosette cells, and terminally differentiated them into DA neurons with GDNF, BDNF, TGF-β3, cAMP and ascorbic acid. After the terminal differentiation, Tuj1 (beta-tubulin class III; a microtubule element expressed exclusively in neurons), TH (tyrosine hydroxylase; a rate-limiting enzyme in the production of dopamine), Nurr1 (nuclear receptor related 1 protein; a key nuclear receptor protein implicated in the DA differentiation of the embryonic brain), Pitx3 (paired-like homeodomain 3, a essential transcription factor in the development and survival of A9 midbrain DA neurons), and AADC (aromatic-L-amino-acid decarboxylase; a key enzyme in the formation of biogenic trace amines such as DA and serotonin)-expressing cells were detected by immunostaining using antibodies against Tuj1, TH, Nurr1, Pitx3, and AADC ([Figure 6](#F6){ref-type="fig"}). Our result indicated that the PD-iPSCs we generated retained potential to differentiate into DA neurons *in vitro*. The possibility of using the PD-DA neurons as a cell model for research and clinical purposes is under investigation.

Many studies have recently demonstrated patient-specific iPSCs as an important source for cell models to study etiopathophysiology of several diseases. For example, a progressive degeneration of motor neurons was observed during differentiation from spinal muscular atrophy (SMA)-iPSCs ([@B7]). Cardiomyocytes derived from LEOPARD syndrome iPSCs were found to reflect the hypertrophic features related to this disease ([@B1]). Similarly, cardiomyocytes produced from Long QT and Timothy syndrome patient iPSCs had the prolonged duration of action potentials, as is seen in these patients ([@B22]; [@B34]). RETT syndrome patient iPSCs reproduced the decreased number of glutamatergic synapses and calcium transients, as might be relevant to the clinical features of RETT ([@B20]). Familial dysautonomia iPSC-derived neural crest precursor cells exhibited reduced neurogenic differentiation and migration associated with these disease phenotypes ([@B16]). Smooth muscle cells differentiated from Hutchinson-Gilford progeria patient iPSCs gave rise to premature senescence, vascular aging defects seen in patients ([@B17]; [@B35]). Importantly, the defects of neurons derived from SMA-, familial-dysautonomia-, and RETT-iPSCs were partially ameliorated by the treatment with small-molecule candidates or previously reported candidate drugs, further supporting the idea that disease specific-iPSCs would provide cell models for research and clinical purposes ([@B7]; [@B16]; [@B20]).

Our group has recently established iPSCs from fibroblasts of patients with CCALD and AMN and used the cells to generate cell models to study X-linked Adrenoleukodystrophy (X-ALD) ([@B12]). Oligodendrocytes differentiated from CCALD-iPSCs displayed a significant accumulation of intracellular very long chain fatty acids (VLCFAs), recapitulating pathophenotypical characteristics observed in the patients with this disease. Furthermore, we also observed a decrease in the accumulated VLCFA by chemical treatment to induce expression of the closest homolog of the *ABCD1* transporter, *ABCD2*. Therefore, the cell model derived from CCALD-iPSCs would be potentially of great use in screening or testing the efficacy of new drugs to treat patients suffering from CCALD.

Herein, we have shown the establishment of iPSCs from patients who were previously diagnosed with sporadic or familial diseases and the potential of iPSCs to differentiate into disease-relevant cells. The generated disease-specific iPSC lines were exclusively stored and maintained by the Stem Cell Bank in Korea and are available to all researchers who study the pathophysiologies of incurable diseases and drug discovery ([Table 3](#T3){ref-type="table"}). Recent studies regarding disease models developed from patient-derived iPSCs have shown the effectiveness of disease-specific iPSCs in terms of potentials in specialized cell differentiation, understanding human disease mechanisms and new drug screening. Although the field of iPSCs has developed rapidly in the past several years, the field remains relatively young and holds many questions to be answered.

Methods
=======

Culture of fibroblasts
----------------------

Primary fibroblast of patients with Parkinson\'s disease (PD, AG20442), Alzheimer\'s disease (AD, AG07889), juvenile-onset, type I diabetes mellitus (JDM, GM01911), Duchene type muscular dystrophy (DMD, GM05128), and normal control fibroblasts (HDFn, SKU\#C-004-5C) were purchased from Coriell and Invitrogen. Purchased primary fibroblasts were cultured under culture conditions recommended by the manufacturers.

Retroviral transduction and maintenance of iPSCs
------------------------------------------------

A pMSCV vector containing a *c-MYC* human sequence and pMIG vectors containing *OCT4*, *SOX2*, and *KLF4* human sequences were obtained from Addgene. 293GPG cells were transfected using retroviral vectors. A day after transfection, viral supernatants were collected for a 9 day-long period. Obtained supernatants were concentrated by ultracentrifugation. Primary skin fibroblasts were transduced for a day and on the 5th day post infection, infected cells were re-plated onto STO feeder cells. Re-plated cells were cultured in hESC medium including basic fibroblast growth factor (bFGF; 10 ng/ml) for 3-4 weeks. Apparent colonies on STO feeder cells were mechanically picked and transferred once every week. After 10 passages, the concentration of bFGF was changed to 4 ng/ml.

Alkaline phosphatase staining and immunocytochemistry
-----------------------------------------------------

Alkaline phosphatase staining was performed following the manufacturer\'s recommended procedure (Sigma-Aldrich). Cells were fixed in 4% paraformaldehyde for 30 min, permeabilized with 0.1% Triton X-100 for 10 min, and blocked in 2% BSA in PBS for 1 h. Cells were then incubated with the appropriate primary antibodies against NANOG (R&D systems), OCT4 (Santa Cruz), SOX2 (Chemicon), SSEA4 (Chemicon), TRA-1-81 (Chemicon), TRA-1-60 (Chemicon), HNF3β (Santa Cruz), Brachyury (Santa Cruz), PAX6 (DSHB), Tuj1 (COVANCE), Nestin (Chemicon), TH (Pelfreez), Nurr1 (Millipore), Pitx3 (Millipore), and AADC (Millipore). Appropriate Alexa Fluor 488- or 568-labeled secondary antibodies (Molecular Probes) were treated for 1 h.

Gene expression analysis
------------------------

Total RNA preparation was conducted for iPSCs, control hESCs, and fibroblasts using the Total RNA extraction kit (Intron Biotechnology) and converted to complementary DNA using the iScript™ cDNA Synthesis Kit (BIO-RAD). Semi-quantitative RT-PCR was performed with EmeraldAmp GT PCR Master Mix (Takara Bio Inc.) and quantitative RT-PCR was carried out using specific primers ([@B25]). Quantitative RT-PCR was performed with SYBR premix Ex taq (Takara Bio Inc.) in the C1000™ thermal cycler (BIO-RAD).

DNA fingerprinting analysis
---------------------------

PCR based DNA fingerprint analysis of iPSCs were performed by Humanpass Inc. (Seoul, Korea) using a standard protocol for short tandem repeats (STR).

Karyotype analysis
------------------

Chromosomal studies were performed at GenDix, Inc. (Seoul, Korea) using standard protocols for GTG banding.

Differentiation of iPSCs into three-germ layer cell types
---------------------------------------------------------

Disease-specific iPSCs were washed with PBS and 2 mg/ml collagenase was introduced for an hour. Detached colonies were collected, washed with EB medium (80% DMEM/F12, 20% KO serum replacement, 1 mM L-glutamine, 0.1 mM nonessential amino acids, 0.1 mM 2-mercaptoethanol, 100 U/ml penicillin and 100 µg/ml streptomycin) and gently resuspended in EB medium with 5% FBS. EBs were formed by culturing colonies in suspension and the medium was changed every other day. Suspension culture was continued for a week and EBs were then attached onto Matrigel (BD) coated culture dishes. They were maintained for an additional 7 days for differentiation and the medium was changed every other day.

Differentiation of iPSCs into DA neurons
----------------------------------------

Differentiation of DA neurons was performed according to our established protocols with a slight modification ([@B5]; [@B13]). First, iPSCs were washed with PBS and 2 mg/ml collagenase was introduced for an hour. Following our previously established protocol, EBs were cultured for 4 days in the presence of DM and SB ([@B13]).

For differentiation to DA neurons, EBs were attached onto Matrigel-coated culture dishes and cultured for 5 days to generate neural rosette structures expressing neural stem cell markers such as Nestin and Pax6. Neural rosettes were isolated mechanically to obtain a high population of neural precursor cells (NPCs), and they were cultured on Matrigel-coated culture dishes for expansion. In order to induce DA neurons, NPCs were cultured in medium with SHH and FGF8 for 8 days and terminally differentiated in the presence of GDNF, BDNF, TGF-β3, cAMP and ascorbic acid in the culture medium for about 2 weeks.
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![Both disease-specific and wild-type iPSC lines expressing pluripotent markers similar to hESCs. PD-iPSC4, PD-iPSC10, AD-iPSC6, AD-iPSC7-5, JDM-iPSC1, DMD-iPSC4, DMD-iPSC5, WT-iPSC1, and WT-iPSC3 were derived from patient-derived fibroblasts as well as normal neonatal human dermal fibroblasts as shown in [Table 1](#T1){ref-type="table"}. The derivation of CCALD- and AMN-iPSC lines has been previously reported ([@B12]). All established iPSC colonies exhibited hESC-like morphology. Moreover, the established iPSC lines showed alkaline phosphatase (AP) activity and expressed pluripotency markers. 4,6-Diamidino-2-phenylindole (DAPI) staining was used to determine the total cell content in the image. Scale bars = 200 µm.](emm-44-202-g001){#F1}

![Pluripotency-associated genes in disease-specific cell lines show expressions similar to the levels of hESCs. Quantitative real-time PCR showed the total expression levels of reprogramming factors, *OCT4*, *SOX2*, *KLF4*, and *c-MYC* as well as the pluripotency-related factors *NANOG* and *hTERT* in hESCs (H9), the indicated parent fibroblasts (hFib), and iPSC lines. Distinct expressions similar to those of hESCs, but different from those of the parent fibroblasts were observed in most of the genes. However, expression levels of *KLF4* were high even in most of the fibroblasts when compared to those of hESCs. H9 is a human ES cell line used as a positive control. PCR reactions were normalized against internal controls (β-actin) and plotted relative to expression levels in the hESC control. HDFn, normal neonatal human dermal fibroblasts.](emm-44-202-g002){#F2}

![Analysis for the reactivation of endogenous pluripotency-related genes such as *OCT4*, *SOX2*, *KLF4*, and *c-MYC* in iPSC lines. The semi-quantitative RT-PCR analysis showed the relative expression levels of four pluripotency-promoting genes: *OCT4*, *SOX2*, *KLF4*, and *c-MYC* in PD-, AD-, JDM-, DMD-, WT-iPSCs, and their fibroblasts. Specific primers were used to determine the expression levels of endogenous (Endo), virally-delivered transgenes (Trans) and the total expression (Total) for each cell line. All the disease-specific iPSC lines showed reactivation of endogenous reprogramming transcription factors while the expressions of retrovirus-delivered transgenes were reduced to low or undetectable levels in the iPSC lines. hESCs and fibroblasts were used as positive and negative controls. GAPDH shown at the bottom was used as a loading control for each lane.](emm-44-202-g003){#F3}

![Disease-specific and wild-type iPSC lines have normal karyotypes. When chromosomal contents were analyzed with high resolution G-banding karyotypes, the cell lines, which included PD-iPSC4, PD-iPSC10, AD-iPSC6, AD-iPSC7-5, JDM-iPSC1, DMD-iPSC4, DMD-iPSC5, WT-iPSC1, and WT-iPSC3 at over 20 passages, indicated normal diploid chromosomal contents.](emm-44-202-g004){#F4}

![EB-based differentiation of iPSC lines reveals three lineage-specific marker expressions. Disease-specific and wild-type iPSC lines were spontaneously differentiated in hESC medium without bFGF for the formation of EBs. Two weeks later, EBs were attached on a gelatin coated dish and allowed to differentiate into all three germ layers for 10 days. Immunostaining was performed using antibodies specific to ectoderm (Nestin, green; Pax6, red), endoderm \[AFP (α-fetoprotein), green; HNF3β, red\], and mesoderm (Brachyury, green) lineages. Scale bars = 100 µm.](emm-44-202-g005){#F5}

![Differentiation of PD-iPSCs into DA neurons. The identity of DA neurons was confirmed *via* TH positive neurons co-expressing Tuj1, Nurr1, Pitx3, AADC. The total cell content in the merged image was represented via DAPI (blue) staining. Scale bar = 100 µm.](emm-44-202-g006){#F6}

###### 

Fibroblasts of patients with sporadic or familial diseases were used to generate iPSC lines

![](emm-44-202-i001)

Generation of CCALD- and AMN-iPSCs was previously reported ([@B12]), and these cell lines are being stored with other cell lines and open to researchers as shown in [Table 3.](#T3){ref-type="table"}

###### 

The genetic identity of disease-specific and wild-type iPSCs to their parental fibroblasts was confirmed by DNA fingerprinting analysis

![](emm-44-202-i002)

DNA fingerprinting analysis performed at 16 independent loci of STR (short tandem repeats) confirmed that iPSC lines have identical genetic information to their parental fibroblasts.

###### 

List of iPSC lines in Korea Stem Cell Bank (<http://koreastemcellbank.org/>)

![](emm-44-202-i003)

17 cell lines are being distributed for research purposes.
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